Significance of Targeted Sequencing Assay for Patients with Suspected Myeloid Malignancies.
10.19746/j.cnki.issn.1009-2137.2020.06.031
- Author:
Li-Juan ZHANG
1
;
Yu-Ye SHI
1
;
Yue CHEN
1
;
Yuan DENG
1
;
Yi-Han DING
1
;
Zan LI
1
;
Kan-Kan CHEN
1
;
Bang-He DING
1
;
Chun-Ling WANG
1
;
Liang YU
1
;
Zheng-Mei HE
2
Author Information
1. Department of Hematology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Key Laboratory of Hematology of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China.
2. Department of Hematology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Key Laboratory of Hematology of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China E-mail: hzm0907@126.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Myeloid, Acute/genetics*;
Middle Aged;
Mutation;
Myelodysplastic Syndromes/genetics*;
Myelodysplastic-Myeloproliferative Diseases;
Patients
- From:
Journal of Experimental Hematology
2020;28(6):1985-1990
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical significance of the targeted next-generation sequencing assay for patients with suspected myeloid malignancies.
METHODS:A total of 39 hematopenia patients with suspected myeloid malignamies in Department of Hematology of The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University from January 2018 to April 2019 were treated, 20 hot spot genes of myelodysplastic syndrome (MDS) were detected.
RESULTS:Regarding the diagnostic type, there were 7 cases of idiopathic cytopenia of undetermined significance (ICUS), 8 cases of clonal cytopenias of undetermined significance (CCUS) and 24 cases of myeloid myeloid malignancies which included 18 cases of MDS, 4 cases of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and 2 cases of acute myeloid leukemia. Positive mutation was detected in 70.8% (17/24) of myeloid malignancy patients , and 72.7% (16/22) in MDS and MDS/MPN patients. The main mutation types were ASXL1, TET2 and RUNX1. Compared with gene negative group, there were no significant differences in sex, age (＜60 years old or ≥60 years old), proportion of bone marrow blast cells (＜5% or≥5%) and cytogenetics (good, medium and poor) (P＞0.05). Furthermore, all 8 CCUS patients showed positive mutation, and the incidence of double or multiple mutation in CCUS group was significantly lower than that of the MDS and MDS/MPN group (37.5% vs 54.5%) (P=0.002). The mutation types between the two groups were similar, and there was no significant difference in variant allele frequency (P＞0.05).
CONCLUSION:Our results suggest that there are high rates of double or multiple mutations in myeloid malignancies, especially in patients with MDS and MDS/MPN. Targeted sequencing assay can improve the diagnosis of myeloid malignancies, and guide clinical treatment.
